Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2021)

Historic Non-Current Debt for Inhibikase Therapeutics (IKT) over the last 2 years, with Q2 2021 value amounting to $248911.0.

  • Inhibikase Therapeutics' Non-Current Debt changed N/A to $248911.0 in Q2 2021 from the same period last year, while for Jun 2021 it was $248911.0, marking a year-over-year change of. This contributed to the annual value of $276461.0 for FY2020, which is N/A changed from last year.
  • According to the latest figures from Q2 2021, Inhibikase Therapeutics' Non-Current Debt is $248911.0.
  • Inhibikase Therapeutics' 5-year Non-Current Debt high stood at $276461.0 for Q4 2020, and its period low was $248911.0 during Q1 2021.